Skip to main content
SpringerLink
Log in

Nail Reactions to Anticancer Therapies

  • Chapter
Scher and Daniel’s Nails

Abstract

Anticancer therapies, including cytotoxic chemotherapies and targeted biologic therapies are well known to cause adverse reactions in the skin. The effect of anticancer treatments on the nails has only recently been appreciated. Although the nail changes are often asymptomatic, they can be associated with pain or functional impairment. Many of the cytotoxic chemotherapies result in changes to the nail bed or nail plate, while the newer targeted therapies tend to affect the periungual region. This chapter highlights how to recognize and manage the nail changes seen with cytotoxic chemotherapies as well as targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 84.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J. Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Support Care Cancer. 2008;16:267–73.

    Article  PubMed  Google Scholar 

  2. Lacouture ME, Maitland M, Segaert S, Setser A, Baran R, Fox LP, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18(4):509–22.

    Article  PubMed  Google Scholar 

  3. Charles C, Sultan S, Bungener C, Mateus C, Lanoy E, Dauchy S, et al. Impact of cutaneous toxicities associated with targeted therapies on quality of life. Results of a longitudinal exploratory study. Bull Cancer. 2013;100:213–22.

    Article  PubMed  Google Scholar 

  4. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40:367–98.

    Article  CAS  PubMed  Google Scholar 

  5. Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract. 2009;15:143–55.

    Article  CAS  PubMed  Google Scholar 

  6. Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16:e181–9.

    Article  CAS  PubMed  Google Scholar 

  7. Shah PC, Rao KR, Patel AR. Cyclophosphamide induced nail pigmentation. Br J Dermatol. 1978;98:675–80.

    Article  CAS  PubMed  Google Scholar 

  8. Borecky DJ, Stephenson J, Keeling JH, Vukelja SJ. Idarubicin-induced pigmentary changes of the nails. Cutis. 1997;59:203–4.

    CAS  PubMed  Google Scholar 

  9. Piraccini BM, Tosti A. Drug-induced nail disorders: incidence, management and prognosis. Drug Saf. 1999;21:215–21.

    Article  Google Scholar 

  10. Bird BR, Elfiki T, Tucker O, O'Reilly S. Unilateral nail changes secondary to adriamycin: the protective effect of brachial plexopathy. Ann Oncol. 2006;17:527.

    Article  CAS  PubMed  Google Scholar 

  11. Hinds G, Thomas V. Malignancy and cancer treatment-related hair and nail changes. Dermatol Clin. 2008;26:59–68.

    Article  CAS  PubMed  Google Scholar 

  12. Shelly W, Humphrey GB. Transverse leukonychia (Mee’s lines) due to daunorubicin chemotherapy. Pediatr Dermatol. 1997;14:144–5.

    Article  Google Scholar 

  13. Ceyhan AM, Yildirim M, Bircan HA, Karayigit DZ. Transverse leukonychia (Mees’ lines) associated with docetaxel. J Dermatol. 2010;37(2):188–9.

    Article  PubMed  Google Scholar 

  14. Lehoczky O, Pulay T. Transverse leukonychia secondary to paclitaxel-carboplatin chemotherapy in a patient with ovarian cancer. J Obstet Gynaecol. 2002;22:694.

    Article  CAS  PubMed  Google Scholar 

  15. Chen GY, Chen HY, Hsu MM, Tsao CJ, Chen WC. Onychomadesis and onycholysis associated with capecitabine. Br J Dermatol. 2001;145:521–2.

    Article  CAS  PubMed  Google Scholar 

  16. Piraccini BM, Iorizzo M. Drug reactions affecting the nail unit: diagnosis and management. Dermatol Clin. 2007;25:215–21.

    Article  CAS  PubMed  Google Scholar 

  17. Wasner G, Hilpert F, Baron R, Pfisterer J. Clinical picture: nail changes secondary to docetaxel. Lancet. 2001;357:910.

    Article  CAS  PubMed  Google Scholar 

  18. Nakamura S, Kajita S, Takagi A, Hashimoto Y, Ishida-Yamamoto A, Takahashi H, et al. Improvement in docetaxel-induced nail changes associated with cyclooxygenase-2 inhibitor treatment. Clin Exp Dermatol. 2009;34:e320–1.

    Article  CAS  PubMed  Google Scholar 

  19. Alimonti A, Nardoni C, Papaldo P, Ferretti G, Caleno MP, Carlini P, et al. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res. 2005;25(5):3531–2.

    PubMed  Google Scholar 

  20. Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS. Onycholysis as a complication of systemic chemotherapy: report of five-cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer. 2000;88:2367–71.

    Article  CAS  PubMed  Google Scholar 

  21. Lau CP, Hui P, Chan TC. Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. Chin Med J. 2011;124:2559–60.

    PubMed  Google Scholar 

  22. Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol. 2003;26:435–6.

    Article  PubMed  Google Scholar 

  23. Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–9.

    Article  PubMed  Google Scholar 

  24. Scotte F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–31.

    Article  PubMed  Google Scholar 

  25. Chen GY, Chen W, Huang WT. Single transverse apparent leukonychia caused by 5-fluorouracil plus leucovorin. Dermatology. 2003;207(1):86–7.

    Article  PubMed  Google Scholar 

  26. Bianchi L, Iraci S, Tomassoli M, Carrozzo AM, Nini G. Coexistence of apparent transverse leukonychia (Muehrcke’s lines type) and longitudinal melanonychia after 5-fluorouracil/adriamycin/cyclophosphamide chemotherapy. Dermatology. 1992;185(3):216–7.

    Article  CAS  PubMed  Google Scholar 

  27. Uyttendaele H, Geyer A, Scher RK. Drugs and nails. J Eur Acad Dermatol Venereol. 2004;18:124–5.

    Article  CAS  PubMed  Google Scholar 

  28. McGrath SE, Webb A, Walker-Bone K. Bleomycin-induced Raynaud’s phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. J Clin Oncol. 2013;31:e51–2.

    Article  PubMed  Google Scholar 

  29. Reiser M, Bruns C, Hartmann P, Salzberger B, Diehl V, Fatkenheuer G. Raynaud’s phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi’s sarcoma. Eur J Clin Microbiol Infect Dis. 1998;17:58–60.

    Article  CAS  PubMed  Google Scholar 

  30. Piraccini BM, Iorizzo M, Tosti A. Drug-induced nail abnormalities. Am J Clin Dermatol. 2003;4:31–7.

    Article  PubMed  Google Scholar 

  31. Paul LJ, Cohen PR. Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail. J Drugs Dermatol. 2012;11(2):262–8.

    PubMed  Google Scholar 

  32. Piguet V, Borradori L. Pyogenic granuloma-like lesions during capecitabine therapy. Br J Dermatol. 2002;147:1270–2.

    Article  CAS  PubMed  Google Scholar 

  33. Wantzin GL, Thomsen K. Acute paronychia after high-dose methotrexate therapy. Arch Dermatol. 1983;119:623–4.

    Article  CAS  PubMed  Google Scholar 

  34. Manalo FB, Marks A, Davis HL Jr. Doxorubicin toxicity. Onycholysis, plantar callus formation, and epidermolysis. J Am Med Assoc. 1975;233:56–7.

    Article  CAS  Google Scholar 

  35. Freiman A, Bouganim N, O’Brien EA. Case reports: mitoxantrone – induced onycholysis associated with subungual abscess, paronychia, and pyogenic granuloma. J Drugs Dermatol. 2005;4(4):490–2.

    PubMed  Google Scholar 

  36. Nicolopoulos J, Howard A. Docetaxel-induced nail dystrophy. Australas J Dermatol. 2002;43(4):293–6.

    Article  PubMed  Google Scholar 

  37. Tiseo M, Leprovite M, Ardizzoni A. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents. 2004;4:139–48.

    Article  CAS  PubMed  Google Scholar 

  38. Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol. 2007;56:460–5.

    Article  PubMed  Google Scholar 

  39. Peuvrel L, Querex G, Brocard A, Saint-Jean M, Dreno B. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Dermatology. 2012;224:204–8.

    Article  CAS  PubMed  Google Scholar 

  40. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803–12.

    Article  CAS  PubMed  Google Scholar 

  41. Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2012;67:400–8.

    Article  CAS  PubMed  Google Scholar 

  42. Sibaud V, Dalenc F, Mourey L, Chevreau C. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol. 2011;91:584–5.

    Article  CAS  PubMed  Google Scholar 

  43. Lee MW, Seo C, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84:23–6.

    Article  CAS  PubMed  Google Scholar 

  44. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317–26.

    Article  PubMed  Google Scholar 

  45. Chang GC, Yang T, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:4646–8.

    Article  PubMed  Google Scholar 

  46. Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol. 2010;24:958–60.

    Article  CAS  PubMed  Google Scholar 

  47. Sibaud V, Robert C. Pigmentary disorders induced by anticancer agents. Part II: targeted therapies. Ann Dermatol Venerel. 2013;140:266–73.

    Article  CAS  Google Scholar 

  48. Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol. 2006;72:63–4.

    Article  CAS  PubMed  Google Scholar 

  49. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. 2006;5:228–31.

    PubMed  Google Scholar 

  50. Steele JC, Triantafyllou A, Rajlawat BP, Field EA. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib. Clin Exp Dermatol. 2012;37(4):432–3.

    Article  CAS  PubMed  Google Scholar 

  51. Das A, Podder I, Kumar D, Ghosh A, Shome K. Imatinib-induced transverse melanonychia: an unusual presentation. Indian J Dermatol. 2015;60(4):412–3.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Bitar C, Farooqui MZ, Valdez J, Saba NS, Soto S, Bray A, Marti G, Wiestner A, Cowen EW. Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152(6):698–701.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRT-142886). Investig New Drugs. 2011;29:1114–21.

    Article  CAS  Google Scholar 

  54. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther. 2011;24:396–400.

    Article  PubMed  Google Scholar 

  55. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16:557–66.

    Article  CAS  PubMed  Google Scholar 

  56. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144:886–92.

    Article  CAS  PubMed  Google Scholar 

  57. Robert C, Faivre S, Raymond E, Armand J-P, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med. 2005;143:313–4.

    Article  PubMed  Google Scholar 

  58. Hong J, Park S, Choi SJ, Lee SH, Lee KC, Lee JI, et al. Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol. 2007;37:424–8.

    Article  PubMed  Google Scholar 

  59. Galimont-Collen AF, Vos L, Lavrijsen AP, Ouwekerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845–51.

    Article  CAS  PubMed  Google Scholar 

  60. Scheinfeld N, Dahdah MJ, Scher R. Vitamins and minerals: their role in nail health and disease. J Drugs Dermatol. 2007;6:782–7.

    Google Scholar 

  61. Lacouture ME, Anadkat M, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–95.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Winther D, Saunte D, Knap M, Haahr V, Jensen AB. Nail changes due to docetaxel: a neglected side effect and nuisance for the patient. Support Care Cancer. 2007;15:1191–7.

    Article  PubMed  Google Scholar 

  63. Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs. 2007;30(4):S17–26.

    Article  PubMed  Google Scholar 

  64. Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol. 2006;154:191–2.

    Article  PubMed  Google Scholar 

  65. Hachisuka J, Yunotani S, Shidahara S, Moroi Y, Furue M. Effect of adapelene on cetixumab-induced painful periungual inflammation. J Am Acad Dermatol. 2011;64:e20–1.

    Article  PubMed  Google Scholar 

  66. Daniel CR, Iorizzo M, Piraccini BM, Tosti A. Grading simple chronic paronychia and onycholysis. Int J Dermatol. 2006;45(12):1447–8.

    Article  PubMed  Google Scholar 

  67. Kiyohara Y, Yamakazi N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69:463–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. New York Presbyterian/Weill Cornell Medicine, New York, NY, USA

    Marisa Kardos Garshick

  2. Memorial Sloan-Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA

    Patricia L. Myskowski

Authors
  1. Marisa Kardos Garshick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia L. Myskowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Pennsylvania, Philadelphia, PA, USA

    Adam I. Rubin

  2. Brown University, Providence, RI, USA

    Nathaniel J. Jellinek

  3. Department of Dermatology, University of Mississippi Medical Center, Jackson, MS, USA

    C. Ralph Daniel III

  4. Department of Dermatology, Weill Cornell Medical College, New York, NY, USA

    Richard K. Scher

27.1 Electronic Supplementary Material

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Garshick, M.K., Myskowski, P.L. (2018). Nail Reactions to Anticancer Therapies. In: Rubin, A.I., Jellinek, N.J., Daniel, C.R., Scher, R.K. (eds) Scher and Daniel’s Nails. Springer, Cham. https://doi.org/10.1007/978-3-319-65649-6_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-65649-6_27

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-65647-2

  • Online ISBN: 978-3-319-65649-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation